Abstract:Background A number of clinical trials evaluated the efficacy and adverse effects of oral propranolol in the treatment of infantile hemangioma (IH), but the treatment has not yet been standardized. This meta-analysis aims to reevaluate the efficacy and adverse effects of oral propranolol in comparative studies and to provide a reliable basis for clinical administration in the therapy for IH. Methods Data were obtained from PubMed, Embase, Cochrane Library, Web of Science, China National Knowledge Infrastructure and Wanfang database, from inception to December 1st, 2018. The pooled risk ratios (RR) with 95% confidence intervals (95% CI) were calculated and used to evaluate the effect size. The meta-analysis was performed using the random-effects model due to heterogeneity between the studies. The Cochrane Collaboration 6 aspects of bias, methodological index for non-randomized studies and the Newcastle–Ottawa Scale were used to assess the risk for bias. Sensitivity analysis, publication bias and subgroup analysis were performed. Results Eighteen unique studies involving 2701 unique children were included in the analysis. The response rate was reported in 18 trials, which compared oral propranolol with other treatments. The heterogeneity was statistically significant ( P < 0.00001, I 2 = 95%). The difference in the response rate was statistically significant (RR = 1.40, 95% CI 1.13–1.75) while compared with the controls. However, no significant difference in the adverse events rate (RR = 0.78, 95% CI 0.45–1.34) and relapse rate (RR = 1.45, 95% CI 0.66–3.16) were found. Otherwise, the subgroup analysis indicated that the RR was 1.64 (95% CI 0.24–11.36) for low-dose propranolol (1 mg/kg/day), 1.42 (95% CI 1.12–1.80) for medium dose (2 mg/kg/day) and 1.46 (95% CI 1.17–1.82) for high dose (3 mg/kg/day), but the high dose had higher adverse events rate than medium dose, with 3.60% and 86.22%, respectively. The effectiveness of propranolol therapy among cases of treatment duration less than 6 months (RR = 1.24, 95% CI 1.05–1.47) was inferior to that of treatment duration greater than or equal to 6 months (RR = 1.46, 95% CI 1.11–1.92). Conclusions This meta-analysis reveals that oral propranolol is superior to other treatments in improving response rate of IH and can be used as the first-line therapy for IH children. A dosage of 2 mg/kg/day propranolol orally may be a good choice for IH. However, further studies are essential.

Propranolol inhibits the angiogenic capacity of hemangioma endothelia via blocking β-adrenoceptor in mast cell

Efficacy and adverse effects of oral propranolol in infantile hemangioma: a meta-analysis of comparative studies

Propranolol inhibits stemness of hemangioma through Jagged1

Mechanisms of propranolol action in infantile hemangioma

Combinative effects of β -elemene and propranolol on the proliferation, migration, and angiogenesis of hemangioma

R(+) Propranolol decreases lipid accumulation in hemangioma-derived stem cells

Role of Thrombospondin-1 and Nuclear Factor-κB Signaling Pathways in Antiangiogenesis of Infantile Hemangioma

Propranolol for the treatment of infantile hemangiomas: a nine-year monocentric experience from a tertiary hospital

Shikonin reverses pyruvate kinase isoform M2-mediated propranolol resistance in infantile hemangioma through reactive oxygen species-induced autophagic dysfunction

Continuous Delivery of Propranolol from Liposomes-in-microspheres Significantly Inhibits Infantile Hemangioma Growth

Safety assessment of propranolol for infantile hemangioma: a study in an Asian population

Efficacy and Safety of Oral Propranolol or Topical Timolol for the Treatment of Superficial Infantile Hemangiomas

Efficacy and safety of atenolol versus propranolol for treatment of infantile haemangioma: A narrative review

The efficacy and safety of treatments for infantile hemangiomas: a Bayesian network meta-analysis

Effectiveness of Propranolol in the Treatment of Infantile Hemangioma Beyond the Proliferation Phase

Oral atenolol treatment for infantile hemangiomas: clinical analysis of 133 consecutive patients

The Efficacy and Safety of Treatments for Infantile Hemangiomas: a Bayesian Network Meta‐analysis

Insights into the mechanisms of angiogenesis in infantile hemangioma

Propranolol inhibits cavernous vascular malformations by β1 adrenergic receptor antagonism in animal models

Cardiac Evaluation before and after Oral Propranolol Treatment for Infantile Hemangiomas

Efficacy of propranolol for cutaneous hemangiomas in premature children